| 注册
首页|期刊导航|中国药物评价|HPLC-一测多评法测定参葛补肾胶囊中总黄酮醇苷的含量

HPLC-一测多评法测定参葛补肾胶囊中总黄酮醇苷的含量

李成功 胡时先 任宾 潘树球 徐海燕 王涵斌 郝娟

中国药物评价2024,Vol.41Issue(3):198-203,6.
中国药物评价2024,Vol.41Issue(3):198-203,6.

HPLC-一测多评法测定参葛补肾胶囊中总黄酮醇苷的含量

Simultaneous Determination of Total Flavonol Glycosides in Shenge Bushen Capsule by HPLC-QAMS

李成功 1胡时先 1任宾 1潘树球 2徐海燕 1王涵斌 1郝娟1

作者信息

  • 1. 新疆华春生物药业股份有限公司,新疆乌鲁木齐 830000
  • 2. 国药集团德众(佛山)药业有限公司,广东佛山 528000
  • 折叠

摘要

Abstract

Objective:To develop a HPLC method for determination of icariin,epimedin A,epimedin B,epimedin C in Shenge Bush-en capsule.Methods:The chromatographic was performed on a Waters ACQUITY UPLC ® HSS T3 C18column(2.1 × 100 mum,1.8 µm),with acetonitrile(A)-0.05%phosphoric acid solution at the flow rate of 0.3 mL·min-1.Detection wavelength was set at 320 nm,the column temperature was maintained at 30 ℃,and the injection volume was 2 μL.The relative correction factors(fs/k)of the other three components was calculated by slope correction method with icariin as internal reference substance.Results:The linear range of icar-iin,epimedin A,epimedin B and epimedin were 7.13~713.38 μg·mL-1(r=0.999 9),1.28~128.40 μg·mL-1(r=0.999 9),5.11~510.80 µg·mL-1(r=0.999 9),4.36~435.67 μg·mL(r=0.999 9),respectively.The average recoveries were 104.56%,99.69%,100.00%,98.59%,and the RSDs were 1.4%,2.7%,1.2%,2.8%,respectively.By slope correction method,fs/k of epi-medin A,epimedin B and epimedin C were 1.31,1.19,1.17.There were no significance difference in content determination results be-tween two correction methods of QAMS and external standard(P>0.05).Conclusion:The method is simple,accurate and sensitive,and can be used for the quality control study of total Flavonol Glycosides in Shenge Bushen Capsule.

关键词

参葛补肾胶囊/总黄酮醇苷/高效液相色谱/一测多评法

Key words

Shenge Bushen capsules/Total flavonol glycosides/High performance liquid chromatography(HPLC)/Quantitative analy-sis of multi-components by single marker(QAMS)

分类

医药卫生

引用本文复制引用

李成功,胡时先,任宾,潘树球,徐海燕,王涵斌,郝娟..HPLC-一测多评法测定参葛补肾胶囊中总黄酮醇苷的含量[J].中国药物评价,2024,41(3):198-203,6.

基金项目

国家重大新药创制科技重大专项资助(2018ZX09731020) (2018ZX09731020)

中国药物评价

2095-3593

访问量0
|
下载量0
段落导航相关论文